IMRAN IQBAL: Open Payments
NPI 1306070040 · ELIZABETHTOWN, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,884 in 179 payments from 16 companies in 2025. Trend: 2023 $1,503 · 2024 $1,793 · 2025 $2,884
Food & beverage: $2,884
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $392 |
| Neurocrine BioSciences, Inc. | 26 | $376 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $274 |
| Vanda Pharmaceuticals Inc. | 10 | $271 |
| Alkermes, Inc. | 12 | $239 |
| ABBVIE INC. | 23 | $229 |
| E.R. Squibb & Sons, L.L.C. | 14 | $191 |
| Corium, LLC | 10 | $144 |
| Axsome Therapeutics, Inc. | 12 | $136 |
| Noven Therapeutics, LLC | 7 | $134 |
Products named: INGREZZA, CAPLYTA, FANAPT, ABILIFY MAINTENA, REXULTI, LYBALVI, VRAYLAR, COBENFY.
Industry payments across KY — which companies pay providers there.
